Loss of exclusivityApril 2034latest FDA-listed patent expiry
CompanyAOP HEALTH US LLC
Drug detail
Brand name
RAPIBLYK
Active ingredient
LANDIOLOL HYDROCHLORIDE
Strength
EQ 280MG BASE/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
Modality
Small molecule
FDA approval
November 2024
Marketing status
RX
Listed patents
Patent
Expires
Type
10722516
April 2034
use U-4235
Regulatory exclusivity
Code
Expires
NCE
November 2029
NPP
February 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.